Media coverage about Eiger BioPharmaceuticals (NASDAQ:EIGR) has been trending somewhat positive recently, Accern Sentiment reports. Accern identifies negative and positive media coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Eiger BioPharmaceuticals earned a media sentiment score of 0.10 on Accern’s scale. Accern also gave headlines about the biotechnology company an impact score of 46.1816532982812 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the near future.

Several research analysts have commented on the company. Wedbush reissued an “ourperform” rating and set a $34.00 target price on shares of Eiger BioPharmaceuticals in a research note on Monday, August 14th. Zacks Investment Research downgraded Eiger BioPharmaceuticals from a “hold” rating to a “sell” rating in a research note on Wednesday, August 16th. Piper Jaffray Companies reissued a “buy” rating and set a $36.00 target price on shares of Eiger BioPharmaceuticals in a research note on Tuesday, August 15th. ValuEngine raised Eiger BioPharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Tuesday, November 14th. Finally, Oppenheimer set a $34.00 price objective on Eiger BioPharmaceuticals and gave the company a “buy” rating in a research note on Monday, October 23rd. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and six have issued a buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus target price of $30.43.

Eiger BioPharmaceuticals (NASDAQ EIGR) opened at $11.80 on Tuesday. Eiger BioPharmaceuticals has a 52 week low of $6.10 and a 52 week high of $13.95. The company has a current ratio of 5.78, a quick ratio of 5.78 and a debt-to-equity ratio of 1.19.

Eiger BioPharmaceuticals (NASDAQ:EIGR) last released its quarterly earnings data on Thursday, November 9th. The biotechnology company reported ($1.10) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($1.28) by $0.18. analysts anticipate that Eiger BioPharmaceuticals will post -5.08 EPS for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: This article was originally posted by Watch List News and is the sole property of of Watch List News. If you are accessing this article on another site, it was illegally stolen and reposted in violation of United States & international trademark & copyright law. The legal version of this article can be viewed at

Eiger BioPharmaceuticals Company Profile

Eiger BioPharmaceuticals, Inc, formerly Celladon Corporation, is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of products for the treatment of orphan diseases. Its pipeline includes Sarasar (lonafarnib) for hepatitis delta virus (HDV), exendin (9-39) for severe hypoglycemia, and Bestatin (ubenimex) for pulmonary arterial hypertension (PAH) and lymphedema.

Insider Buying and Selling by Quarter for Eiger BioPharmaceuticals (NASDAQ:EIGR)

Receive News & Ratings for Eiger BioPharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eiger BioPharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.